Home > Dermatology > EADV 2020 > JAK Inhibitors – A Fascinating Novel Drug Class > Topical JAK inhibition: a novel treatment option for patients with mild-to-moderate AD

Topical JAK inhibition: a novel treatment option for patients with mild-to-moderate AD

Presented By
Prof. Megan Landis, University of Louisville School of Medicine, USA
Conference
EADV 2020
Trial
Phase 2
According to a phase 2b study, brepocitinib cream could be an interesting novel option for patients with mild-to-moderate atopic dermatitis (AD). The brepocitinib cream showed a significant 75% decrease in EASI score at week 6 compared with a vehicle cream, as well as a higher rate of EASI 90 response and a fast and significant antipruritic effect. The topical tyrosine kinase (TYK)2/Janus kinase (JAK)1 inhibitor brepocitinib is a single-molecule designed to target 2 key pathways that play a role in both psoriasis and AD. Inhibition of TYK2 blocks the Th17 axis, which is important in psoriasis but also in specific forms of AD, for example in Asian patients with AD and paediatric new-onset AD. In contrast, inhibition of JAK1 blocks the Th2-pathway, the relevant pathway in European and American AD patients. Prof. Megan Landis (University of Louisville School of Medicine, USA) presented promising results of a double-blind, vehicle-controlled, phase 2b s...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on